Fetal sheep cells

animal tissue

provenance:animal tissue

first introduced:1931

regulatory status:grey market

context:Paul Niehans first used animal-tissue injection in 1931 with calf parathyroid material during an emergency case at his Bern surgical practice. He subsequently standardized on fetal lamb tissue as the donor source for his cellular-therapy protocol at Clinique La Prairie at Clarens. Fetal tissue was selected on the premise of higher 'cellular vitality' and the assumed absence of immune-reactive markers in fetal cells. Those assumptions set the template for the protocol that the clinic used for the remainder of Niehans's career.

MECHANISM CLAIMED

Cells from a specific organ of a freshly killed lamb fetus, when injected into a human recipient, will migrate selectively to the corresponding organ in the recipient and restore its function through cellular replacement and rejuvenation.

MECHANISM ACTUAL

No evidence demonstrates organ-specific migration, durable integration, or restoration of a corresponding human organ after subcutaneous or intramuscular injection of these preparations. Swiss authorities describe fresh-cell therapy as unproven and carrying substantial health risks.

INTERVENTIONS USING IT

Cellular therapy (Frischzellentherapie)

NOTES

Fetal sheep cells, in the Niehans protocol, are macerated tissue preparations from a freshly killed lamb fetus, selected for organ correspondence with the recipient organ targeted for treatment. The preparation is administered subcutaneously or intramuscularly within hours of harvest. The selection of fetal tissue rests on the premise that fetal cells are biologically more potent and less immunogenic than adult cells, but no controlled evidence demonstrates the cross-species, organ-specific cellular replacement that the Niehans protocol claims. Live animal-cell use is regulated as xenotransplantation in Switzerland and requires federal authorization; Swissmedic and the FOPH reported in 2015 that no relevant authorization had been granted.